Ginkgo Bioworks Facing Steep Decline, Analyst Recommends Sell

Monday, 20 May 2024, 16:40

An analyst downgrades Ginkgo Bioworks stock, citing concerns about revenue growth forecasts, business plan changes, and delisting risks. The company's stock has dropped over 10% following a significant decline in Q1 revenue. With a potential 37.5% downside, investors are urged to approach with caution and consider alternative investment opportunities.
https://store.livarava.com/864fc491-16c8-11ef-a6c5-63e1980711b2.jpg
Ginkgo Bioworks Facing Steep Decline, Analyst Recommends Sell

Is Ginkgo stock a sell?

Why rate Ginkgo stock a sell? Where shall I begin?

  1. Massaro is most concerned with management commentary that new "cell programs" are no longer a great forecaster of revenue growth.
  2. The company received a warning from the NYSE and is at risk of delisting.
  3. Ginkgo cut costs significantly, but through troubling moves in headcount and research and development.

Before you buy stock in Ginkgo Bioworks, consider this:

  • The Motley Fool recommends exploring alternative investment options that could offer better returns.
  • Stock Advisor service provides guidance on successful investing strategies and stock picks.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe